Product NDC: | 50242-053 |
Proprietary Name: | Rituxan |
Non Proprietary Name: | rituximab |
Active Ingredient(s): | 10 mg/mL & nbsp; rituximab |
Administration Route(s): | INTRAVENOUS |
Dosage Form(s): | INJECTION, SOLUTION |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 50242-053 |
Labeler Name: | Genentech, Inc. |
Product Type: | HUMAN PRESCRIPTION DRUG |
FDA Application Number: | BLA103705 |
Marketing Category: | BLA |
Start Marketing Date: | 19971126 |
Package NDC: | 50242-053-06 |
Package Description: | 1 VIAL, SINGLE-USE in 1 CARTON (50242-053-06) > 50 mL in 1 VIAL, SINGLE-USE |
NDC Code | 50242-053-06 |
Proprietary Name | Rituxan |
Package Description | 1 VIAL, SINGLE-USE in 1 CARTON (50242-053-06) > 50 mL in 1 VIAL, SINGLE-USE |
Product NDC | 50242-053 |
Product Type Name | HUMAN PRESCRIPTION DRUG |
Non Proprietary Name | rituximab |
Dosage Form Name | INJECTION, SOLUTION |
Route Name | INTRAVENOUS |
Start Marketing Date | 19971126 |
Marketing Category Name | BLA |
Labeler Name | Genentech, Inc. |
Substance Name | RITUXIMAB |
Strength Number | 10 |
Strength Unit | mg/mL |
Pharmaceutical Classes | CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC] |